Dr. Nicolaus Kröger is Professor of Medicine and Medical Director of the Department of Stem Cell Transplantation at the University Medical Center Hamburg-Eppendorf, Germany. Prof. Kröger is board certified in Hematology-Oncology and Internal Medicine.
Since 2018 he is President of the European Society of Blood and Marrow Transplantation (EBMT).
He served also as chairman of the German Stem Cell Working Group (DAG-KBT) from 2014-2020 and is member of several editorial boards such as Blood, Haematologica, Bone Marrow Transplantation and Biology ofBlood and Marrow Transplantation. He is also member of numerous Scientific Committees such as ASH, EHA, and ESH.
He has received several awards for his work to date including the prestigious EBMT van Bekkum Award in 2015. In 2020 he was awarded as Doctor Honoris Causa from the University Belgrade.
Prof. Kröger has published extensively in his area of expertise and has contributed to more than 700 publications in peer-reviewed journals such as NEJM, Lancet, JCO, JNCI, PNAS, Blood and Leukemia.
Professor Arnon Nagler, MD, MSc
Chaim Sheba Medical Center, Israel
Director of the Division of Hematology, Chaim Sheba Medical Center, Israel
Director of Bone Marrow transplantation and Cord Blood Bank, Chaim Sheba Medical Center, Israel
Professor of Medicine at the Tel Aviv University, Tel Aviv, Israel
One of the pioneers of the non-myeloablative and reduced intensity/toxicity allogeneic transplantations for both malignant and non-malignant disorders (Blood 1998)
Established the first public cord blood bank and performed the first cord blood transplanataion in Israel
Leader of the Alternative donor subcommittee of the ALWP of the EBMT from 2008-2010
Leader of the RIC subcommittee of the ALWP of the EBMT – since 2010
Serves on the Editorial Board of several BMT and Hematology Journals and is a Section Editor for Leukemia
Chair of the Acute Leukemia Working Party (ALWP) of the EBMT
Dr Nagler received his medical training at the Hebrew University-Hadassah Medical School, Jerusalem, Israel; he then carried out a Postdoctoral research fellowship in hematology and bone marrow transplantation at “Stanford University Hospital” Palo Alto, CA, in the USA, from 1986 to 1990.
Dr Nagler serves on the Board of Directors of Netcord organization of cord blood banks and was the Netcord Threasurer from 2010-2013.
Dr Nagler has received several awards including the best scientific abstract award of the ASBMT/CIBMR Tandem meeting (2004) and the best clinical abstract award of the NMDP Council Meeting (2004). In addition, Dr Nagler is a popular speaker and has made numerous, invited, international presentations and many Oral presentations on almost annual basis in all international transplantation and hematology meetings – ASH,ASBMT/CIBMTR, EBMT, EHA, Exp Hematology (including a presentation at the presidential symposium) and invited presentation at the Gordon conference (Boston USA).
Dr. Mahmoud Aljurf is the Director of Adult Stem Cell Transplantation and Cell Therapy Program and Deputy Director of the Oncology Centre at King Faisal Specialist Hospital & Research Centre in Riyadh, Saudi Arabia. He received his M.D. degree in 1985, completed his internship at King Khaled University Hospital and subsequently, completed his residency training in Internal Medicine at Brigham and Women’s Hospital, Harvard Medical School, and combined Hematology & Oncology Fellowships at Stanford University Medical Center. He also received Master’s in Public Health (MPH) from Johns Hopkins University and FRCPath degree from the United Kingdom.
Dr. Aljurf is American Board certified in Internal Medicine, Medical Oncology, Hematology, Medical Management and Quality Assurance, he has published over 300 scientific papers, several book chapters and the Lead Editor for the EBMT/ESH book on “Congenital and Acquired Bone Marrow Failure” and Co-Editor for Springer Publisher book “Establishing a Hematopoietic Stem Cell Transplant Unit: A Practical Guide”. Dr. Aljurf is the Editor-in-Chief for the Elsevier journal “Hematology/Oncology and Stem Cell Therapy”.
He was the recipient of the American College of Physicians (ACP) Mastership Award for the year 2012 and the recipient of The Center for International Blood and Marrow Transplant Research (CIBMTR) Distinguished Service Award for the year 2018.
Prof. Francis Ayuk is a hemato-oncologist and clinical investigator with special interest in stem cell
transplantation and cellular therapies; currently deputy director of the Department of Stem Cell Transplantation
at the UKE in Hamburg, and leads the CAR-T cell therapy program.
Andrea Bacigalupo has been the Head of Hematology at the San Martino Hospital Genova Italy (1990-2014) , then at Gemelli -Catholic University Rome (2015-2019) and is currently Consultant at Gemelli Hospital in Rome. He has been involved in stem cell transplants since 1976, and has played an active role in the European Group for Blood and Marrow Transplants (EBMT) since 1977. He was Secretary of EBMT 1982-1986, chairperson of the SAA WP 1984-1990 and President of EBMT 1998-2002. He has conducted several prospective clinical trials in patients with aplastic anemia and in patients undergoing allogeneic transplants: in particular he has been the principal investigator of several prospective randomized studies in the field of GvHD. His main interests are bone marrow failure, GvHD and related complications. He is a member of several national and international hematology societies. He is Associate Editor of the journal Bone Marrow Transplantation and Biology of Blood and Marrow Transplantation and has published over 600 articles in peer-reviewed journals. His current H index is 94.
Renato Bassan is Director of the Hematology Unit at Venice Hospitals, Italy. Dr Bassan obtained his degree in medicine and completed his postdoctoral fellowship in haematology at Padua University, Italy. He then started his work as a full-time haematologist at Bergamo Hospital, Italy, where he set up the leukaemia diagnostic section, the autologous bone marrow transplantation section and the leukaemia clinics. Dr Bassan was trained in onco-haematology at St Bartholomew’s Hospital in London, UK, reaching the position of Honorary Consultant before assuming his current position in 2011. Dr Bassan’s main professional interest is therapy of acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). He has led several prospective Phase 2 and 3 trials for the Northern Italy Leukemia Group (NILG), and is involved in new studies and collaborations with the Italian Group for Haematological Diseases in Adults (GIMEMA) and the European Working Group on Adult ALL (EWALL).
Ali Bazarbachi, MD, PhD is a Professor of Medicine (Hematology and Oncology), Professor of Anatomy, Cell Biology and Physiological Sciences, Associate Dean for basic research, and Director of the bone marrow transplantation program at the American University of Beirut-Medical Center. He received his MD and PhD degrees, residency and fellowship training at the University of Paris VII in France. Dr. Ali Bazarbachi’s research focuses on developing oncogene-targeted therapies for human leukemia and lymphoma as well as post-transplant pharmacological interventions. He has co-authored more than 300 articles in leading scientific journals including The New England Journal of Medicine, Science, Journal of Experimental Medicine, The Lancet Oncology, Journal of Clinical Oncology, Nature Communication, Blood, Leukemia, Cell Death and Differentiation, Oncogene, and Cancer Research, and serves as a reviewer for many of these journals. He is the Chairman of the EMBMT Leukemia Working Party, Chairman of the NCCN Lymphoma Group for Middle East and North Africa, past President of the Lebanese Society of Hematology, and Associate Editor of Bone Marrow Transplantation.
Michael R. Bishop, MD
Dr. Bishop is Professor of Medicine and the Director of the David and Etta Jonas Center for Cellular Therapy at the University of Chicago. Dr. Bishop’s research focuses on the development and conduct novel clinical trials in hematopoietic stem cell transplantation and cellular therapy. Particular areas of interest include the therapeutic use of T cells to treat hematologic malignancies. In addition, his research program is focused on methods to prevent and treat recurrent disease following hematopoietic stem cell transplantation, with a primary focus on B-cell malignancies.
Didier Blaise, MD is Professor of Medicine at the Aix-Marseille University, Chairman of the Hematology Department and director of the transplant and Immune Cellular therapy program at Institute Paoli Calmettes.
He is a founding member of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), a former president of this society and active member of numerous international scientific societies.
He has conducted numerous national and international clinical trials in the field of hematopoietic stem cell transplantation and is the author or co-author of more than 500 peer reviewed papers and the recipient of many national grants.
Francesca Bonifazi is the Director of the Adult Transplant Program in Bologna, and the head of Advanced Cellular Therapies Unit in Bologna, Italy. She has been the President of the Italian Society of HSCT (GITMO) (2015-19). The major scientific fields of interest are GVHD prophylaxis, transplantation from alternative donors, transplantation in the elderly, transplantation in acute leukemia, early complications.
Chiara Bonini, M.D., Professor of Hematology at the University Vita-Salute, San Raffaele, Head of
the Experimental Hematology Unit and Deputy Director of the Division of Immunology,
Transplantation and Infectious Diseases of OSR. She was trained in Milano (Ospedale San Raffaele
– OSR), New York (MSKCC) and Seattle (FHCRC). She has been a member of the Boards of ESGCT
and ASGCT and chair of the EBMT CTIWP. She is currently member of the ASH Awards and Global
Research Award Committees, of the Board of ESH, member of the EHA Subcommittee on Cellular
Therapy and Councelor of the Board of EHA. Her main research focus is allogeneic stem cell
transplantation and the development, preclinical and clinical validation of cell and gene therapy
approaches to treat cancer.
Deputy Director of the Department of Hematology, Oncology and Immunology
Section Head, Cellular Therapy Unit at the Carreras Leukemia Center (CLC)
University Hospital Gie ß en and Marburg, Campus Marburg
Philipps University Marburg
1990 – 1998 Medical School Berlin (Humboldt University Charit é
1998 – 2000 Internship at the University Hospital Benjamin Franklin, Berlin
2000 – 2012 Specialised in Internal Medicin and Hematology and Oncology at the University Hospital Gie ß en and Marburg
2010 – Associate Professor of Molecular Hematology University Hospital Gie ß en and Marburg
2014 – Professor, Internal Medicine and Hematology University Hospital Gie ß en and Marburg
Christian Chabannon is a specialist in Onco-hematology and Medical Oncology, board certified in his home country: France. After training at the Universities of Lyon and Grenoble, and as a research associate at the Transplantation Biology Program, Clinical Research Division, Fred Hutchinson Cancer Research Center in Seattle, WA, USA, he joined the Institut Paoli-Calmettes, Comprehensive Cancer Center in Marseilles, France. He currently holds the position of Chair and Qualified person for the Cellular Therapy Facility at this institution. Additionally, he is a Professor of Medicine in Cell Biology at Aix-Marseille Université School of Medicine. Dr Chabannon held a number of positions in advisory boards for French health authorities and was the Chair of Cancéropôle PACA, the PACA District Regional Research Council from 2010 through 2015. He is currently the Chair of the EBMT Cellular Therapy & Immunobiology Working Party; as such, he was part of the EBMT team effort to adapt the EBMT registry in order to allow registration and capture of follow-up of patients treated with approved CAR-T Cells, in close interactions with national and EU health authorities, including EMA, and with Marketing Approval Holders; as part of this initiative, EBMT works with all interested parties including professional associations at national and EU levels in order to promote transparent and global evaluation of this new class of medicinal products.
Dr. Yi-Bin Chen is the Director of the Hematopoietic Cell Transplantation and Cell Therapy Program at Massachusetts General Hospital (MGH) and an Associate Professor of Medicine at Harvard Medical School in Boston, MA. He completed his undergraduate studies at Yale University, majoring in Molecular Biophysics & Biochemistry before conducting his medical studies at Harvard Medical School. He completed internship and residency at MGH before Hematology / Oncology fellowship at the Dana-Farber Harvard Combined Program. Prior to joining the MGH faculty in 2008, he served as Chief Resident at MGH.
Dr. Chen spends his time primarily as a clinician and clinical researcher. He has conducted analyses and clinical research involving multiple aspects of improving care for patients undergoing autologous and allogeneic HCT. These include establishing BEAM as the standard conditioning regimen for lymphoma patients undergoing autologous HCT, defining autologous HCT as a standard of care for patients with central nervous system involvement of lymphoma, investigating novel targets for the prevention and treatment of both acute and chronic GVHD and pioneering work involving the incorporation of targeted maintenance therapy after allogeneic HCT to prevent disease relapse. Specifically, he has recently led phase III trials involving JAK inhibitors and monoclonal antibodies targeting mediators of lymphocyte trafficking to prevent and treat acute GVHD and is co-chair of an international phase 3 randomized study investigating the use of the FLT3 inhibitor Gilteritinib as maintenance therapy after HCT for patients with FLT3-ITD AML. He was the chair of the 2021 BMT CTN State of the Science Symposium Myeloid Malignancies Committee and serves as the inaugural Executive Committee Chair for the Mt. Sinai Acute GVHD International Consoritum (MAGIC).
Dr. Chen lives in Needham, MA. He is married and enjoys watching his daughter ride horses and his son play basketball. He relishes spending time on the water with his family along the coastline of Cape Cod, MA.
Selim Corbacioglu is Professor and Chair of the Department of Hematology, Oncology and Stem Cell Transplantation at the Children’s Hospital in Regensburg, Germany. Professor Corbacioglu’s research interest is focused on curative options for hemoglobinopathies, and transplant-related systemic endothelial complications such as VOD/SOS and PRES. He was the PI of the multicentre defibrotide prevention trial in children and is the PI for a prospective international trial to evaluate haploidentical HSCT as a curative option for patients with sickle cell disease. The recipient of the Van Bekkum Award of the EMBT in 2010, Professor Corbacioglu is author or senior author of numerous peer-reviewed articles published in the New England Journal of Medicine, Lancet, Blood, Leukaemia and Bone Marrow Transplantation among others. He is the current scientific council chair and the chair of the Pediatric Disease Working Party of the EBMT.
Rafael de la Cámara is a clinical haematologist involved in SCT activities for the last 35 years with particular interest in infectious complications, particularly viral infections. He has been a member of the EBMT and IDWP since 1992. Furthermore, he participated in several studies and guidelines of the IDWP, and also with associations/groups in his country (Spain) related to SCT: Chairman of the IDWP of the Spanish Group of SCT (GETH) (1998-2004); Member of the Executive Board of the Spanish Hematology Association (2001-2015), Executive Board of GETH (2001-2003), Advisory Committee of the National Transplant Organization (2004-2016), and Member of the National Committee of Hematopoietic Progenitor Transplants (Ministry of Health) (2004-2016), expert of the Spanish Medicines Agency (2009-ongoing)(AEMPS). Since May 2020 he am the Chair of the IDWP of EBMT. In the last 2 years, the IDWP has been involved in several studies and recommendations for SARS-CoV-2 in HSCT patients.
Rafael F. Duarte, MD, PhD, FRCP (Lon)
Prof. Duarte is Head of the Department of Hematology and Transplantation Programme at the Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain and is Profesor Asociado de Hematología – Universidad Autónoma de Madrid
Carlo Dufour chairs the “Hemato-Oncology-SCT Department and the Hematology Unit of G. Gaslini Children’s Hospital, Genova, Italy. In this Department have seat the National Registry of Neutropenia, the National Registry of Alps and related disorders, the national Database of Fanconi Anemia and 75 clinical trials were or are still conducted. He authored or co-authored over 260 international publications, various hematology textbook chapters and co-edited a textbook called Congenital and Acquired Bone Marrow Failure and the EBMT handbook. He acts as reviewer for top-ranking journals including the New England Journal of Medicine, Journal of Clinical Oncology, Leukemia, Clinical Immunology, and Blood. He serves as expert evaluator for different institutions including the French Registry for Rare Diseases, the Fanconi Anemia Research Fund Inc. (USA), the Leukemia and lymphoma Research Foundation (UK), and the American Society of Hematology Education Program. From 2014 to 2018 he acted as Chairman of the Working Party of the Severe Aplastic Anemia of the EBMT. He also serves as the Charmain of the Scientific Working Group on Granulocyte and Constitutional Marrow Failure Disorders of the European Hematology Association (EHA). He acts as expert advisor for the drug licensing for the European Medical Agency (EMA) and for the Italian Drug Agency (AIFA).
In 2015 he received from the Fanconi Anemia Research Fund Inc. the Discovery Award for partecipating to the identification of gene FANCT. Since 2019 is member of the Scientific Committee of Marrow Failure of the American Society of Hematology. In 2019 he was awarded by the Spanish” Fundacion en la Anemia de Fanconi” for special scientific contribution in the field of Fanconi Anemia. In 2020 he was recognized by the EBMT with the Van Bekkum award for the best clincal trial: “RACE. Randomized controlled study comparing horse ATG plus CsA with horse ATG plus CsA plus Eltrombopag for the front- line treatment of Acquired Severe Aplastic Anemia”.
Hermann Einsele, MD, FRCP, is Full Professor of Internal Medicine and has been Director of the Department of Internal Medicine II of the University Hospital Würzburg, Germany (since 2004).
Following his medical training at the Universities of Tübingen, Manchester, and London, Professor Einsele became a research fellow in the Department of Haematology, Oncology, Rheumatology, and Immunology at the University of Tübingen, Germany. He was board certified in Internal Medicine in 1991 and in Haematology/Oncology in 1996. In 1999 was promoted as an Associate Professor. He is a visiting professor at the Fred Hutchinson Cancer Research Center in Seattle, WA, USA, and at the City of Hope Hospital, Duarte, CA, USA.
2011-2015 Hermann Einsele was Vice Dean of the Faculty of Medicine of the University of Würzburg, since 2015 he is Vice President of the Julius Maximilians University of Würzburg.
In 1999, he became Chairman of the German Study Group Multiple Myeloma. In 2003, he received the van Bekkum Award, the highest Annual European award for research in the field of stem cell transplantation. In 2011 he was elected as an Honorary Fellow of the Royal College of Pathologists (London), in 2012 Nobel Lecturer Stem Cell Biology/ Transplantation, Nobel Forum Karolinska Institute, and 2014 Member of the Academy of Sciences and Literature, Mainz.
He published more than 600 articles in peer-reviewed journals.
Prof. Einsele is expert in the field of multiple myeloma and stem cell transplantation and has pioneered the use of immunotherapy with selected T cells and bispecific antibodies.
Professor of Hematology, ‘Sapienza’ University of Rome. He earned his medical degree in Turin, Italy, and specialized in pediatrics and in hematology. Worked at the MRC Leukaemia Unit, Hammersmith Hospital, London between 1976 and 1979. Sabbatical at Memorial Sloan-Kettering Cancer Center, New York, between 1991 and 1992.
He is part of the European LeukemiaNet (ELN) Steering Committee and referee for national and international funding agencies. Chairman of the Scientific Committee of the 4th EHA Congress, Barcelona 1999, councilor of EHA until December 2002, and member of the Education Committee of EHA until December 2005. President-Elect, President and Past-President of EHA during the years 2007-2013. Chairman Education Committee and Outreach Unit of EHA up to June 2017. Member of EHA’s Global Outreach Committee.
Chairman of the GIMEMA Working Party for chronic lymphoproliferative disorders, and member of the board of the Working Party for acute leukemias.
Has authored over 750 papers, reviews and books. Has been co-editor of Leukemia and Lymphoma, and associate editor of the British Journal of Hematology and of The Hematology Journal. Editor-in-chief of The Hematology Journal up to December 2004 and of Haematologica from January 2005 to February 2008.
Gösta Gahrton, MD, PhD., Professor emeritus in Medicine at the Karolinska Institute, Stockholm is a leading hematologist worldwide. He was Head of the Department of Medicine, Karolinska University Hospital, Huddinge, in 1985 -1998 and has been chairman of the Nobel committee at the Karolinska Institute, President of the European Group of Blood and Marrow Transplantation (EBMT) and of the World Marrow Donor Association ( WMDA ). He is honorary member of many international Societies among them the EBMT and has received several international Awards, among them the Robert A. Kyle Life Time Achievement Award in 2013. He is editor of the book ”Multiple Myeloma and related disorders” Arnold, London 2004. His research area is hematological malignancies with focus on translational research and clinical application of stem cell transplantation, particularly in multiple myeloma.
Sergio A. Giralt, MD Melvin Berlin Family Chair in Myeloma Research
Deputy Head, Division of Hematologic Malignancies
Attending Physician, Adult BMT Service
Professor of Medicine Weill Cornell Medical College
Memorial Sloan Kettering Cancer Center
Sergio Giralt received his medical degree from Universidad Central de Venezuela. He completed his residency at Good Samaritan Hospital and his fellowship at The University of Texas MD Anderson Cancer Center. In addition to his positions at Memorial Sloan Kettering Cancer Center, Dr. Giralt is Professor of Medicine at Weill Cornell Medical College and the Melvin Berlin Family Chair in Myeloma Research.
Dr. Giralt is an active member of several professional societies, including the American Society of Hematology, the American Society of Clinical Oncology, the North American Society of Blood and Bone Marrow Transplantation (ASBMT), the International Society of Hematotherapy and Graft Engineering, and the Gerontological Society of America. He previously served as chairperson on the executive board of the Center for International Blood and Marrow Transplant Research and the steering committee of the Blood and Marrow Transplant Clinical Trials Network, and he is past president of ASBMT.
A board-certified hematologist/oncologist whose clinical practice and research focus on stem cell transplantation for patients with blood disorders, Dr. Giralt with his colleagues pioneered the use of reduced-intensity conditioning regimens for older or more debilitated patients with blood cancers. Currently, Dr. Giralt’s research is examining the use of T-cell depletion techniques to dramatically reduce the risk of graft-versus-host disease. He has published and presented extensively on these topics. Additionally, Dr. Giralt has served as the principal investigator for a number of clinical trials that examine new treatment approaches for multiple myeloma and other blood cancers that aim to reduce symptom burden and improve treatment tolerability.
Since 2005 Professor Hartmut Goldschmidt is the leader of the Multiple Myeloma Section at the Medical Department V, Heidelberg University Clinic and National Center of Tumor Diseases (NCT) in Heidelberg. After his graduation from medical school and his licensing as a practicing physician in 1982, he received the conferment of doctorate in 1984 at the Humboldt-University in Berlin. In 1988 he was recognized as consultant for internal medicine and worked as assistant physician at the University Medical Center for Internal Medicine, Charité Hospital in Berlin. In 1991 he was recognized in the field of “hematology and internal oncology”. In 1997 he qualified as a professor at the Ruprecht-Karls-University in Heidelberg and was subsequently employed there from 1999 through 2005 as leading senior physician. Additionally since 1996, Professor Goldschmidt is the Head of the German-speaking Myeloma Multicenter Group (GMMG). In June of 2018 he accepted the W3 endowed professorship “Translational Myeloma Research” at the University Clinic in Heidelberg. In February 2018 he was awarded the German Cancer Award for Clinical Cancer Research.
Mehdi Hamadani, MD, is a Professor of Internal Medicine at the Medical College of Wisconsin, specializing in lymphoma, cell therapies. Dr. Hamadani also serves as the Director of the BMT & Cellular Therapy Program.
Rupert Handgretinger received his medical degree from the Eberhard-Karls-University in Tübingen in 1986 and was trained at the Children’s University Hospital Tübingen in General Pediatrics and Hematology/Oncology. In 2000, he was appointed as director of the Division of Stem Cell Transplantation at St. Jude Children’s Research Hospital in Memphis, USA, where he served as a full faculty member and Professor of Pediatrics at the University of Tennessee, Memphis, until 2005. From 2005-2021, he was Chairman of the Department of General Pediatrics and Hematology/Oncology at the Children’s University Hospital Tübingen. He retired in April 2021 and is currently senior consultant at the Abu Dhabi Stem Cell Center and professor emeritus at the University of Tuebingen. His main research interests are cellular immunotherapeutic approaches to the treatment of children with various forms of cancer in the context of allogeneic stem cell transplantation. He is especially interested in the establishment of graft engineering techniques to introduce new concepts in haploidentical transplantation and in the elucidation of mechanisms of graft-mediated anti-tumor effects induced by Natural Killer and other effector cells.
Dr Juan Carlos Hernández-Boluda was a resident in the Hematology Service of the Hospital Clínic of Barcelona, where he earned his PhD in Medicine and Surgery with a doctoral thesis entitled: “Role of p16 and survivin in the progression of chronic myeloid leukemia from the chronic phase to the blast crisis”. Since 2001, he has been a consultant at the Hematology Department of the Hospital Clínico Universitario of Valencia, working primarily in the fields of hematopoietic stem cell transplantation and the chronic myeloproliferative neoplasms (MPN). He is an Associate Professor at the Medicine Department of the University of Valencia. Since April 2018, he is Vice-chair of the MPN subcommittee of the Chronic Malignancies Working Party of the EBMT. Currently, he is the President of the Grupo Español de Neoplasias Mieloproliferativas Filadelfia Negativas (GEMFIN). As a result of his scientific activity in these fields, he has published around 150 papers in peer-review international journals.
Dieter Hoelzer is Professor of Medicine and Hematology.
His main research is Acute Leukemias. He founded the German Adult ALL Study Group (GMALL) which so far conducted 7 multicenter studies in >145 participating hospitals, where more than 7000 patients were treated.
Prof. Hoelzer was one of the five founders and former President of the European Hematology Association (EHA), currently Vice President of the European and German Competence Network Leukemias. He also founded the European Working Group on Adult Acute Lymphoblastic Leukemia (EWALL).
He was also the President of the Society for Hemato Oncology (SOHO) and a member of the Medical Council and the Foundation Board of the DKMS (Deutsche Knochenmark Spender Datei). He is the chairman of the Medical Advisory Board of the German Carreras Leukemia Foundation.
Prof. Hoelzer received several awards for cancer research and therapy including those of the German Cancer Society, the “Deutsche Krebshilfe”, the Johann-Georg-Zimmermann-Price, the San Salvatore Award and the European Leukemia Network Merit Award. He is an honorary member of the Hematological Societies of Austria, Hungary and Germany (DGHO) and received the doctor honoris causa from the University of Athens and First Pavlov State Medical University of Saint Petersburg.
Prof. Hoelzer is author or co-author of more than 800 peer-reviewed publications and co-author of international textbooks, such as Oxford textbook of Oncology, 20th edition of Harrison´s principles of Internal Medicine (2018) and its forthcoming 21st edition. In addition, he is the first author of the European Guidelines for adult ALL (ESMO) and a recent editorial for the New England Journal of Medicine.
He Huang, M.D., Ph.D., is the Dean of the First Affiliated Hospital, Zhejiang University School of Medicine; Director of Hematology Institution of Zhejiang University, Hangzhou, China Prof. Huang specializes in clinical and basic research on hematopoietic stem cell transplantation, cellular immunotherapy and stem cell biology research As corresponding author, he has published 167 original papers in SCI cited journals including top journals in the field of hematology, such as Blood, Leukemia, etc. For his outstanding achievement on hematopoietic stem cell transplantation, Prof. Huang was awarded the national prizes twice in 2003 and 2015,
Michael Hudecek performed medical training at the University of Leipzig, Germany, where he also commenced his specialist training in hematology and oncology. In 2007, Michael joined the Fred Hutchinson Cancer Research Center in Seattle as a post-doctoral research fellow, where he trained in the laboratory of Prof. Stanley R. Riddell and worked on identifying and validating novel tumor antigens in hematologic malignancies, the design and functional optimization of chimeric antigen receptor (CAR) constructs, as well as defining optimal cellular compositions of CAR T-cell products. In 2012, Michael was recruited to the Universitätsklinikum Würzburg, Germany, where he established a translational research program on CAR T-cell immunotherapy. At present, this program comprises physicians, scientists, doctoral students, master students and technicians in a multidisciplinary, international team that performs cutting-edge research with focus on novel transformative CAR technologies, and first-in-man clinical application of novel CAR-T products. Michael is an extraordinary member of the Bavarian Academy of Sciences, and recipient of the 2017 Artur Pappenheim Award of the German Society for Hematology and Medical Oncology.
Prof. Dr. Dr. Ulrike Köhl, Ph.D., M.D.
Ulrike Köhl is a full Professor for Immune Oncology at the University of Leipzig, Germany and the director of the Fraunhofer Institute for Cell Therapy and Immunology since 2017 and holds the position of a full Professor and director of the Institute of Cellular Therapeutics at Hannover Medical School since 2012, respectively.
She has studied both, medicine and biology, worked previously at the MD Anderson Cancer Centre in Houston, USA and at the University Hospital, Frankfurt, Germany. She is an international leading expert in the development and manufacturing of cell and gene therapies in cancer and regenerative medicine and collaborates with both international industry and academic partners. She has a specific own research focus on primary human NK cells as well as chimeric antigen receptor (CAR) expressing T and NK effector cells. The Köhl team has been responsible for one of the first NK cell trial in Europe. Currently, she is heading SaxoCell, a cluster for cell and gene therapy, funded by the Germany federal government as a future and excellence initiative. In addition, she is leading two EU consortia (Mature-NK and ImSavar), is member of numerous national and international societies and is serving as a reviewer for the authorities including PEI and EMA, respectively.
Per Ljungman has MD and PhD degrees from the Karolinska Institutet in Stockholm, Sweden. He is board certified in internal medicine and hematology and has spent most of his career at the Karolinska University Hospital where he was director of hematology for more than 15 years. His research interests have been virus infections in patients undergoing allogeneic stem cell transplantation including herpesvirus and community acquired respiratory virus infections most recently SARS-CoV-2. Another of his research interests is vaccination of stem cell transplant patients. He has published extensively on these topics as well as being co-editor of the book Transplant Infections now in its 4th edition..
Per Ljungman has served in many different international organizations including being president of the ICHS, chairman of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the European Conference on Infections in Leukemia (ECIL).
Dr Donal McLornan graduated in 1999 from Queen’s University Belfast with Honours. During his post-graduate training he was awarded a prestigious MRC fellowship and completed a PhD investigating drug resistance in AML. Donal works across London sites– Guy’s Hospital for his myeloid practice and is a consultant in the allogeneic transplant and CAR-T team at University College London Hospital, which has the largest transplant/cell therapy program in the UK. He is the current chair of the Chronic Malignancy Working Party of EBMT.
Giampaolo Merlini received his medical degree and specialized in Hematology and in Laboratory Medicine at the University of Pavia. He was trained by Prof. Jan Waldenström and Prof. Elliott Osserman in the study of monoclonal gammopathies and systemic amyloidosis. He founded and was the Director of the Center for Research and Treatment of Systemic Amyloidosis until 2016, University Hospital Policlinico San Matteo, he was President of the International Society of Amyloidosis from 2005 to 2010. He received several awards, including the 2017 Ham-Wasserman Lecture of the American Society of Hematology, the Robert Kyle Award from the International Workshop on Waldenström’s Macroglobulinemia in 2018, the Jan G. Waldenström Award from the International Myeloma Society in 2019, and the Giampaolo Merlini Award from the International Society of Amyloidosis in 2020.
Dr. Merlini’s research interests include the pathogenesis, natural history, diagnosis and treatment of monoclonal gammopathies, in particular immunoglobulin light chain amyloidosis. His recent research focuses on the investigation of molecular mechanisms of cardiac damage, on biomarkers for assessing prognosis and response to therapy and on the development of novel therapeutic agents and treatment designed in the light of advances in the understanding of the molecular mechanisms of these diseases. He is principal investigator for several research projects in this field.
Malgorzata Mikulska is Associate Professor of Infectious Diseases at the University of Genova (Department of Health Sciences, DISSAL) since 2015, and full time Infectious Diseases Consultant at the Division of Infectious Diseases, IRCCSS Ospedale Policlinico San Martino in Genova, Italy.
She obtained her medical degree at Warsaw Medical University, Poland, subsequently recognized in 2005 by the University of Genova. She completed her specialty training in Infectious Diseases at the University of Genova and obtained PhD degree at Università Cattolica di Roma, Italy.
She is an author or co-author of over 141 documents, mostly indexed international medical journals, with H-index of 34. She is also a co-author of 10 book chapters, including the one of Prophylaxis and Empirical Therapy of Infections in Cancer Patients in “Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases”, 9th Edition. By John E. Bennett, Raphael Dolin, Martin J. Blaser. Elsevier 2020.
Her principal areas of expertise are infections in immunocompromised patients, in particular in patients with haematological disorder and allogeneic haematopoietic stem cell transplant (HSCT) recipients, and diagnosis and treatment of invasive fungal infections.
She is an active member of the following scientific societies:
• Infectious Diseases Working Party (IDWP) of EBMT (The European Group for Blood and Marrow Transplantation), Secretary for years 2016-2020
• European Conference on Infections in Leukemia (ECIL) group since 2009
• European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
o Infectious Diseases Member of Professional Affaires Committee (PAS) of ESCMID
o ESCMID Study Group for Infections in Compromised Hosts (ESGIH)
o ESCMID Fungal Infection Study Group Study Group (EFISG)
• Academy Committee of ECMM (European Confederation of Medical Mycology) and ECCM Fellow since 2016
• Italian society of Infectious diseases and Tropical Medicine (SIMIT)
• Italian Federation of Human and animal Mycopathology (FIMUA) since 2008
Dr Mohamad Mohty is a full Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint Antoine Hospital and Sorbonne University in Paris, France. He obtained his medical degree from the University of Montpellier, France, and PhD from the University of Marseille, France. He is also head of a translational research team ( Inserm ) at the Saint Antoine Research Centre in Paris.
Dr Mohty is the past president of the European Society for Blood and Marrow Transplantation (EBMT), and the current chairman of the Acute Leukemia Working Party of the EBMT . He is also the founder and chairman of the International Academy for Clinical Hematology (IACH) and board member of the EBMT and the Intergroupe Francophone du Myelome (IFM).
In addition to publishing more than 780 peer reviewed articles in the field of stem cell transplantation, leukemia, and myeloma, Dr Mohty also serves as Editor in Chief of the journals Bone Marrow Transplantation and Clinical Hematology International . He also serves as an editor, board member, and/or reviewer across numerous other reputable journals
Philippe Moreau, MD, serves as Professor of Clinical Hematology and head of the translational research program in hematology and oncology, at the University Hospital of Nantes, France. Professor Moreau’s clinical interests are focused on multiple myeloma and its treatment with high-dose therapy and novel agents.
Professor Moreau is the chairman of the Intergroupe Francophone du Myélome (IFM) since 2020.
He is vice-president of International Myeloma Society (IMS) since 2019, and he is a member of the steering committee of the International Myeloma Working Group (IMWG) since 2013. He has served as the principal investigator or co-PI of many international randomized phase 3 clinical trials: Tourmaline (Ixazomib for relapsed myeloma), Aspire (Carfilzomib for relapsed myeloma), Endeavor (Carfilzomib for relapsed myeloma), Stratus (Pomalidomide for relapsed myeloma), Pollux (Daratumumab for relapsed myeloma), Arrow (weekly versus biweekly Carfilzomib for relapsed myeloma), Cassiopeia (Daratumumab for frontline therapy in transplant eligible patients) or Ikema (Isatuximab for relapsed myeloma).
He was a member of the organizing committee for the 2011 International Myeloma Workshop in Paris.
His research is widely published. Professor Moreau has authored or coauthored more than 300 peer-reviewed articles that have appeared in high impact factor journals including, the New England Journal of Medicine, Journal of Clinical Oncology, The Lancet, The Lancet Oncology, and Blood. He is frequently invited to speak at international hematologic oncology meetings.
Professor Moreau received in 2018 the Robert A. Kyle lifetime achievement award.
Consultant Haematologist and Professor of Stem Cell Transplantation at King’s College Hospital and King’s College London
Antonio Pagliuca, Professor of Stem Cell Transplantation at King’s College London, is the Chief Medical and Scientific Advisor (CMSA) for the Anthony Nolan and a trustee for Leukaemia UK. His role as CMSA will be to assess and guide the future medical and scientific priorities for the charity.
Past roles include President of BSBMT, Chair of the BMT CRG and National Clinical Lead for Regenerative Medicine, NHS England; and Medical Director for King’s College Hospital, Networked Care Division.
As Transplant Director for 19 years to 2017, he lead King’s attainment to a Centre of Excellence and one of the largest unrelated, cord, haplo-identical transplant and cellular therapy programs in the UK. In 2018, King’s became the first CAR-T centre in the UK to treat both adult ALL and NHL. He has published widely on haematological malignancies, stem cell transplantation and infections in this patient group.
Francesco Passamonti, MD
Hematology, Department of Medicine and Surgery
University of Insubria, Varese, Italy
Francesco Passamonti is Full Professor of Hematology at the University of Insubria, Varese, Italy, and Head
of the Division of Hematology of Varese. He obtained his medical degree from the University of Pavia,
subsequently becoming a specialist in hematology. He worked as Assistant Professor of Hematology at the
University of Pavia and as a hematologist at the Hematology of the I.R.C.C.S. Policlinico San Matteo, Pavia,
He is principal investigator for many clinical trials in hematologic malignancies; however, his main area of
interest is in the Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) polycythemia
vera, essential thrombocythemia, and myelofibrosis. He collaborated on the definition of the molecular
basis of MPNs and then designed translational studies to evaluate clinical implications of new molecular
discoveries. He designed new prognostic models for essential thrombocythemia (IPSET) and primary
(DIPSS) and secondary myelofibrosis (MYSEC-PM). He leads and with his group perform many clinical trials
on the development of targeted therapies in MPNs. He participated as a panelist in the definitions of
diagnostic criteria, response to treatments, and guidelines for treatment decision. He is a member of the
board of the International Working Group on Myeloproliferative Research and Treatment, as well as the
European LeukemiaNet Work Package 9 for MPN and the Working Party for MPN of GIMEMA. Francesco
Passamonti is a member of several hematology societies and the Editorial Board of the American Journal of
Hematology and is an invited speaker to several international meetings. He has authored and coauthored
more than 250 articles on MPN and other hematological malignancies, reaching an h-index of 66 (Scopus,
Régis Peffault de Latour, MD, PhD Saint-Louis Hospital, Paris Diderot University, Paris, France
Régis Peffault de Latour is Professor of Hematology at the Hematology and Bone Marrow Transplant Department, Saint-Louis Hospital, Paris Diderot University, in Paris, France. He received his MD degree from the Lariboisière Hospital, Paris Diderot University, in 2003, and his PhD in immunology from the Pasteur Institute in Paris in 2006. After training in hematology in Paris, Professor Peffault de Latour completed his postdoctoral fellowship at the Hematology Branch of the National Institutes of Health in Bethesda, MD, USA, from 2008 to 2010. He obtained his tenured professorship position in 2014. Professor Peffault de Latour is responsible for the French Reference Center for Aplastic Anemia and PNH, as well as the French Network for Immuno-Hematological Rare Diseases (MaRIH). He is also Chair of the Severe Aplastic Anaemia Working Party (SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT) and Chair of the bone marrow failure and hematopoietic disorders subnetwork of the European Reference Network in Rare Hematological Diseases (EuroBloodNet). Professor Peffault de Latour’s research interests include bone marrow transplantation, bone marrow failure, and paroxysmal nocturnal hemoglobinuria. He has authored approximately 300 papers cited in PubMed, as well as being a regular peer reviewer for journals like Blood, Haematologica, British Journal of Haematology, Biology of Blood and Marrow Transplantation, and Bone Marrow Transplantation.
Christina Peters is Professor of Paediatrics at the Department of Stem Cell Transplantation of St. Anna Children’s Hospital in Vienna. Her research interests include allogeneic haematopoietic transplantation in children and adolescents with malignant and non-malignant diseases from related and unrelated donors, infectious and toxic complications after stem cell transplantation, adoptive therapies for haematological malignancies and family oriented rehabilitation for children with life threatening diseases.
She is international study chair of the multinational trial investigating the role of TBI vs. Chemo-conditioning in children and adolescents with ALL („FORUM“).
As an expert speaker, Dr. Peters has presented on a variety of topics at many symposia, meetings and seminars. She has authored and co-authored numerous papers in peer-review journals such as Lancet, New England Journal of Medicines, Journal of Clinical Oncology, Biology of Blood and Marrow Transplantation, Bone Marrow Transplantation, Blood, Vox Sanguinis, Leukemia, Haematologica, British Journal of Haematology, and Frontiers.
Prof. Peters is member of many professional societies including IBFM, CIBMTR, EHA and SIOP. Furthermore, Dr. Peters is a member of the Advisory Board of the Austrian Ministry of Health, the Bioethical committee of the Austrian Prime Minister and member of the ENPREMA (European Network Paediatric Research at EMA).
Director of the Medical Clinic I, Hematology and Cellular Therapy at the University Hospital in Leipzig, Germany
After graduating from medical school in 1996, I first started medical training in heart surgery. Since 1998, I have been working at the Department of Hematology and Oncology at the University Hospital “Carl Gustav Carus” in Dresden, Germany. Between 2001 and 2003 I completed a 2-year postdoctoral fellowship provided by the Humboldt-foundation at the Fred Hutchinson Cancer Research Center in Seattle, USA. From 2012 to 2018 I held a position of Professor of Hematology at the University Hospital “Carl Gustav Carus” in Dresden and was the head of the section of Hematology as well as chair of the medical ethics committee of the TU Dresden. In 2015 I was appointed as Transcampus Professor of Hematology at the Faculty of Life Sciences and medicine at King’s College London. Since October 2018 I am heading the Hematology program at the University Hospital in Leipzig as Director of the Medical Clinic I, Hematology and Cell Therapy. I am a steering committee member of the SAL group, speaker of the German MDS study group, I have co-founded the European Myelodysplastic Syndromes Cooperative Group (EMSCO) in 2012 and I am chairing the MDS SWG of the EHA.
Dr. Porter is the Jodi Fisher-Horowitz Professor of Leukemia Care Excellence at the Perelman School of Medicine and Abramson Cancer Center, and Director of Cell Therapy and Transplant at the University of Pennsylvania. He graduated the University of Rochester and earned a medical degree at Brown University, completed internship and residency at Boston University Hospital, and fellowship training at Brigham and Women’s Hospital and Harvard Medical School. Dr. Porter is an accomplished clinical investigator with research interests in development of novel approaches to cellular therapy and stem cell transplantation. He has an extensive publication record and has been the primary or co-author of over 200 research and review articles, and he currently serves as the Deputy Editor of Transplantation and Cell Therapy (formerly Biology of Blood and Marrow Transplantation), and is an Associate Editor for the American Journal of Hematology. Of several major accomplishments, his work with colleagues at the University of Pennsylvania pioneered the successful development of CAR T cells leading to the first FDA approval of gene modified T cells for cancer in 2017.
Dr. Pulsipher is Section Head of Transplantation and Cellular Therapy at Children’s Hospital Los Angeles and Professor of Pediatrics with an endowed Chair of BMT Clinical Research at the USC Keck School of Medicine. He is the immediate past group chair of the Pediatric Blood Transplantation and Cellular Therapy Consortium – an 86-member international clinical trials group—and is recognized as a leading influence in his field, receiving the PTCTC Lifetime Achievement Award this past February at the international TCT meetings. This award is given once yearly to top international leaders in pediatric BMT and cell therapy. He is currently principal or co-principal investigator of six national, multi-center studies and a co-investigator on multiple additional clinical trials. Dr. Pulsipher has authored more than 230 articles in peer-reviewed journals including New England Journal of Medicine, Journal of Clinical Oncology, Journal of Clinical Investigation, Blood, and Nature Genetics. He has also written twelve book chapters and presented widely at national and international conferences. He has significant expertise in allogeneic transplantation for acute leukemias, especially ALL, where he is running national research trials aimed at testing haploidentical approaches, and assessing the role of NGS-MRD in potentially identifying patients able to undergo less intensive BMT approaches, and testing novel CAR T-cell approaches. Dr. Pulsipher also has done extensive work on reducing toxicity approaches to transplantation of both malignant and non-malignant disorders, and he is running national research protocols for patients with immunodeficiencies, HLH, and bone marrow failure. Dr. Pulsipher’s work in Cell therapy helped lead to the FDA approval of the first CART cell treatment, tisagenlecleucel, and he continues at the forefront of the cell therapy field, running trials in CAR T, NK, and Viral Specific T-cell therapies.
Noopur S. Raje, MD, is Professor of Medicine at Harvard Medical School, the director of the Center for Multiple Myeloma, and the Rita Kelley Chair in Oncology at Massachusetts General Hospital Cancer Center in Boston, MA, USA. She studied medicine at B.J. Medical College, Pune University, India, and trained at Massachusetts General Hospital and at the Dana-Farber Cancer Institute, Boston.
Professor Raje’s research focuses primarily on developing novel therapeutic strategies for the treatment of multiple myeloma and related plasma cell disorders, which aims to identify cellular signaling pathways that contribute to the survival and proliferation of myeloma cells in the bone environment and design clinical trials to specifically harness these.
Professor Raje is co-chair of the National Cancer Institute Myeloma Steering Committee, a board member of the International Myeloma Society, a member of the International Myeloma Working Group, and serves on the National Comprehensive Cancer Network Clinical Practice Guidelines Committee for Multiple Myeloma. She has received several awards and has published widely on multiple myeloma.
Alessandro Rambaldi, MD, is Full Professor of Hematology of the Department of Oncology and Hematology at the University of Milan, Italy. Following his medical degree, he was Associate in Pathology at the Dana Farber Cancer Institute, Boston, USA. Since 2006 he is the Director of the Hematology and Bone Marrow Transplant Unit at the Ospedale Papa Giovanni XXIII, Bergamo, Italy. He is member of the American Society of Hematology (ASH), European Hematology Association (EHA), European Blood and Marrow Transplant group (BMT). From 2010 he served JACIE as Vice Chair and Chair from 2010 to 2015. From 2011 to 2014 he was President of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
His scientific interest ranges from translational research to academic clinical trials in which he pioneered the integration of molecular evaluation of minimal residual disease in the treatment strategy of adult patients with acute lymphoblastic leukemia and non-Hodgkin’s lymphomas. He also led several trials in the field of acute leukemia, lymphomas chronic myeloproliferative neoplasms and allogeneic stem cell transplantation. A current special research interest is the development of innovative cellular therapies for the treatment of leukemia relapse after allogeneic stem cell transplantation.
Prof. Alessandro Rambaldi has published more than 530 publications in peer-reviewed journals such as Lancet Oncology, Journal of Clinical Oncology (member of the Editorial Board), Blood and Leukemia for which he routinely serves as referee.
Antonio Risitano is Head of the Hematology and BMT Unit at the AORN San Giuseppe Moscati in Avellino, Italy. He graduated in 1997 from the University of Napoli Federico II Medical School in Naples, Italy, where he also completed a residency in haematology under the mentorship of Professor Bruno Rotoli. In 2000, he was awarded a fellowship at the haematology branch of the National Institutes of Health, where he dedicated his time to experimental work on the pathophysiology of bone marrow failure syndromes, under the guidance of Doctor Neal Young. He then moved back to Naples to complete his PhD, serving as a clinical attendant and subsequent research associate in the haematology unit. Professor Risitano was Director of the Bone Marrow Transplantation Program at the University of Napoli Federico II until July 2020, when he moved to his current role.
Professor Risitano has previously focused his activity on clinical management and basic science in the field of aplastic anaemia, paroxysmal nocturnal haemoglobinuria, and idiopathic acquired cytopenias, as well as stem cell transplantation. He has actively contributed to the progress made in this field, with a number of scientific publications describing both clinical trials and biological insights. His current activity includes the management of patients receiving bone marrow transplantations, as well as of those with any bone marrow failures syndrome, including paroxysmal nocturnal haemoglobinuria. He also runs a number of research activities, both clinical and experimental, in the field of paroxysmal nocturnal haemoglobinuria, aplastic anaemia, and bone marrow transplantation, as well in other malignant and non-malignant haematological diseases. Professor Risitano has authored more than 100 publications in the top haematology journals.
Marie Robin, MD, PhD
Current position: Assistant in Hematology-transplantation department, Saint-Louis Hospital, Paris University, Paris, France
-Responsible of the subcommittee of MDS / Chronic Malignancies Working Party of the EBMT.
-President of the French Society of transplantation and cellular therapy (SFGM-TC)
Main domains of research: myelofibrosis and myelodysplastic syndrome / allogeneic hematopoietic stem cell transplantation
Stefan O. Schönland, MD
Amyloidosis Center Heidelberg
Medical Department V (Haematology / Oncology and Rheumatology with Stem Cell Transplant Unit and CAR T cell program)
University Hospital Heidelberg, Germany
• Professor (apl.) of Internal Medicine
• Senior Consultant
• Board certified in Internal Medicine and Haematology-Oncology
• Founder of the Amyloidosis Center, Heidelberg
• President of the German Society of Amyloid Diseases (DGAK)
• President elect of the International Society of Amyloidosis (ISA)
• Chair of the Plasma Cell Disorder Subcommittee of the Chronic Malignancies Working Party of the EBMT
• EuroBloodNet Member and Heidelberg representative
– Plasma Cell Dyscrasias including AL Amyloidosis and MGCS
– Autologous and Allogeneic Transplantation / Cell therapy
Stephen J. Schuster, MD
Professor of Medicine, University of Pennsylvania
Robert and Margarita Louis-Dreyfus Professor of CLL and Lymphoma
Director, Lymphoma Program and Lymphoma Translational Research
Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
Stephen J. Schuster, MD is the Robert and Margarita Louis-Dreyfus Professor of CLL and Lymphoma and a professor of medicine at the University of Pennsylvania. He is also the Director of the Lymphoma Program and Director of Lymphoma Translational Research at the Abramson Cancer Center. After graduating AOA from Jefferson Medical College and completing his residency at Pennsylvania Hospital, Dr. Schuster completed clinical and research fellowships at the Cardeza Foundation for Hematologic Research. In 1989, he became a member of the Cardeza Foundation at Jefferson Medical College. Dr. Schuster joined the University of Pennsylvania in 1998. Since then, his research has focused on the development and application of novel immunotherapies for B-cell lymphomas and CLL, including autologous tumor-derived vaccines, autologous co-stimulated T-cells, radioimmunotherapy, monoclonal antibody therapy, bi-specific antibody therapy, and adoptive immunotherapy using chimeric antigen receptor modified T cells (CAR-T cells) He has over 300 publications and has received numerous awards for outstanding teaching and research.
Following training in internal medicine and pediatrics at the Harvard Combined Residency Program, Dr. Shah joined the Pediatric Hematology and Oncology Fellowship training program at the NCI and then stayed on at the NCI pursuing a career in clinical research in immunotherapy for children and young adults with high-risk hematologic malignancies. She currently serves as a Lasker Clinical Research Scholar and focuses on the implementation of novel CAR T-cell therapies and exploring the toxicity profile and characteristics of new constructs. Her specific interests are in expanding the therapeutic index of novel CAR T-cell constructs by exploring combinatorial treatment strategies, novel targets and taking these novel strategies in other hematologic malignancies.
Avichai Shimoni, MD. Medical specialist in internal medicine and Hematology. Completed medical education in Hadassah Medical School in Jerusalem in 1988. Had clinical fellowship in bone marrow transplantation in MD Anderson Cancer Center, Houston, Texas, between the years 1998-2000. Currently, the director of the department of Bone Marrow Transplantation and co-director of the Division of Hematology at the Chaim Sheba Medical Center, Tel-Hashomer. Associate Professor of Hematology in Tel-Aviv University.
Robert J. Soiffer, MD, is Chief of the Division of Hematologic Malignancies, Chair of the Executive Committee for Clinical Programs, Vice Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute, and Professor of Medicine and Harvard Medical School. Dr. Soiffer conducts research focused on modulation of immune responses in the setting of hematopoietic stem cell transplantation. The ultimate goal for his clinical trials and research grants is to optimize graft versus leukemia activity without inducing graft versus host disease. Dr. Soiffer is a former President of the American Society for Blood and Marrow Transplantation and Immediate Past-Chair of the Advisory Board for the Center for International Blood and Marrow Transplant Research. He serves on the Executive Steering Committees for Blood and Marrow Transplant Clinical Trials Network. Dr. Soiffer is a member of the Board of Directors for the National Marrow Donor Program and will become chairman of the Board in October 2020. Dr. Soiffer serves on the National Cancer Institute’s Leukemia Steering Committee Dr. Soiffer has co-authored more than 350 peer-reviewed manuscripts and numerous book chapters, review articles, editorials, and monographs. Dr. Soiffer has received several honors and awards including the Casty Family Achievement in Mentoring Award from Dana-Farber, the Brian O’Dell Memorial Research Award from the Leukemia and Lymphoma Society, the Lee M. Nadler “Extra Mile” Award from Dana-Farber, and the George Thorn Award for Outstanding Teaching at Brigham and Women’s Hospital.
Pieter Sonneveld, MD, Ph.D. was born in The Netherlands. He received his medical degree from the Erasmus University in Rotterdam, The Netherlands in 1977. In 1980 he completed a Ph.D. thesis on the pharmacology of Adriamycin in Acute Leukemia at the University of Leiden (DW van Bekkum & HM Pinedo, promotores). He received a Fogarty Fellowship and worked for several years at the National Cancer Institute, Bethesda, USA.
Dr. Sonneveld is Professor of Hematology at the Erasmus MC and Erasmus University Rotterdam and has occupied the Chair of the Erasmus MC Cancer Institute in Rotterdam for 8 years. From 2011 to 2017 he has been the head of the department of Hematology. His research focus is on clinical and translational aspects of diagnostics and drug therapy in multiple myeloma. The myeloma research group in Erasmus MC has been very active in molecular diagnostics and prognostic systems.
He is chairman of the HOVON Myeloma Working Group and he coordinates HOVON and EMN clinical trials for multiple myeloma. Dr. Sonneveld helped to found the European Myeloma Network EMN and has been its chairman since 2005. Within EMN, he coordinates a cooperative network for independent clinical trials in Europe and initiates efforts to create international standards for diagnostics and patient care. EMN currently runs 12 international trials, several of which are independent registration trials for novel treatments.
He has been Board member (2011- ) and President (2017-2019) of the European Hematology Association EHA, and occupies the chair of its Scientific Working Group Committee. He has chaired the Scientific Program Committee of the 19th EHA congress in Milan 2014 and of the EMN Myeloma meetings in 2018 and 2020.
He serves on the Scientific Advisory Boards of the IMF and MMRF and is a member of the International Myeloma Working Group. Dr Sonneveld has been a member of the Editorial Boards of Blood, Leukemia, Eur J Cancer and Haematologica. Dr Sonneveld has authored more than 500 peer reviewed scientific publications and several book chapters (H-factor 95). He has received numerous grants for his research.
In 2015 he was awarded the prestigious international Robert Kyle life time achievements Award in Multiple Myeloma. In 2019 he received the Hubertus Wald Award for Cancer Research from Germany.
Prof. Matthias Stelljes earned his medical degree in Kiel. He is currently professor of medicine at the University of Muenster and responsible for the adult allogeneic stem cell transplant program at the University Hospital. With more than 160 allogeneic transplants for adult patients per year, the transplant program in Muenster is largest transplant centers in Europe.
Prof. Stelljes is conducting research in the field of T‐cell–mediated immune responses after allogeneic stem cell transplantation. His main clinical focus centers on the optimization of treatment strategies for patients with high‐risk/relapsed or refractory hematologic malignancies before and after stem cell transplantation, mainly acute leukemia.
Together with his team, he enrolled substantial numbers of patients in various phase I–III trails, including studies with antiviral drugs, bispecific antibodies / antibody‐drug conjugates, novel approaches in conditioning therapies and GvHD treatment. Prof. Stelljes has published numerous peer‐reviewed papers in journals including Lancet Oncology, Journal of Clinical Oncology, and Blood, either as a main or co‐author.
Marion Subklewe is Head of the Laboratory for Translational Cancer Immunotherapy at the Gene Center, Munich and Professor of Internal Medicine at Ludwig Maximilian University of Munich, Germany. She studied medicine at University Hospital Tübingen and completed her postdoctoral fellowship at Rockefeller University in New York.
Professor Subklewe is current Head of the Immunotherapy Program in Haematology and the CAR T Program at University Hospital Munich, Founder and Speaker of the national “Harmonize MRD Flow” Consortium and member of the ELN Working group on MRD. She is also active in clinical research and has been Principal Investigator in 3 I-IT trials in AML and ALL, as well as in over 30 oligo- and multicentric Phase I trials in leukaemia and lymphoma. In recognition of her work, Professor Subklewe has received numerous honours and awards including the EHA Educational Presentation and ASH Abstract Achievement Awards.
Anna Sureda, (MD, PhD) is nowadays the Head of the Clinical Hematology Department of Institut Català d’Oncologia – Hospitalet, Barcelona. Anna Sureda has focused her career on clinical investigations into the treatment of Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and multiple myeloma patients evaluating novel therapies such as immunotherapy combined with stem-cell transplantation. Dr. Sureda was appointed chairperson of the LWP of the EBMT from 2004 to 2010 and secretary of the same organization from 2010 to 2016. She was recently elected president elect of the Spanish Group of Hematopoietic Stem Cell Transplantation and Cellular Therapy
Marcel R. M. van den Brink, MD, PhD
Alan N. Houghton Chair
Head, Division of Hematologic Malignancies
Attending Physician, Department of Medicine
Member, Immunology Program
Marcel van den Brink is a physician scientist and medical oncologist who performs both laboratory and clinical research related to allogeneic bone marrow transplantation (BMT) and immuno-oncology. He is the Head of the Division of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center (MSKCC) and holds a joint appointment in the Immunology and Transplantation Program of the Sloan Kettering Institute. He is the Co-Director of the Parker Institute for Cancer Immunotherapy at MSKCC and Chairman of the Board of DKMS, an international nonprofit organization devoted to bone marrow donor registration. As a clinical scientist, he is involved in immunotherapeutic trials of cytokines and cell therapies for patients with hematologic malignancies. His laboratory is devoted to the immunology of BMT and he studies immune reconstitution, pathophysiology of graft-versus-host disease, the intestinal microbiota, and chimeric antigen receptor T cells in patients and preclinical models. Both as a Division Head and a laboratory Principal Investigator, he mentors junior faculty members, hematology oncology fellows, postdoctoral fellows, graduate students, and undergraduate students.
COSTEM 2021 – Scientific Program
Chairpersons: Nicolaus Kröger, Arnon Nagler
This site place cookies on your device for reasons including keeping track of your preferences, collecting aggregated statistics to analyze how our site is used. ACCEPT
Privacy, Cookies Policy, General Terms and Conditions of Use
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.